Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | PTAFR | P25105 | 6/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 3/20 | 0.44 |
| ▸ | PTGFR | P43088 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KDM4B | O94953 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13955435 | 0.93 | L3MBTL1 (0.50) | EPHX2L3MBTL1TSHRCNR1NPC1 | |
| SCHEMBL4507646 | 0.90 | PTAFR (0.57) | EPHX2PTAFRL3MBTL1NAMPTPTGFR | |
| SCHEMBL4509962 | 0.90 | EPHX2 (0.58) | EPHX2PTAFRL3MBTL1NAMPTPTGFR | |
| SCHEMBL4509189 | 0.89 | EPHX2 (0.51) | EPHX2PTAFRL3MBTL1NAMPTPTGFR | |
| SCHEMBL4507240 | 0.89 | PTAFR (0.52) | EPHX2PTAFRL3MBTL1NAMPTPTGFR | |
| SCHEMBL4512752 | 0.88 | EPHX2 (0.58) | EPHX2PTAFRL3MBTL1NAMPTPTGFR | |
| SCHEMBL4507410 | 0.87 | PTAFR (0.58) | EPHX2PTAFRL3MBTL1NAMPTMEN1 | |
| SCHEMBL4504537 | 0.86 | EPHX2 (0.50) | EPHX2PTAFRL3MBTL1NAMPTPTGFR | |
| SCHEMBL4499183 | 0.86 | EPHX2 (0.52) | EPHX2PTAFRL3MBTL1NAMPTPTGFR | |
| SCHEMBL4505627 | 0.86 | ALDH1A1 (0.54) | EPHX2PTAFRL3MBTL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7494989-B2 | Pyridine compounds useful as N-type calcium channel antagonists | AJINOMOTO CO., INC. (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20080070903-A1 | NEW PYRIMIDINE DERIVATIVES AND NEW PYRIDINE DERIVATIVES | AJINOMOTO CO., INC (JP) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070903-A1 | NEW PYRIMIDINE DERIVATIVES AND NEW PYRIDINE DERIVATIVES | P2RY10, CACNA1B, CACNA1E | EPHX2 1239/4885PTAFR 1396/4885L3MBTL1 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.